Answer
Rifampicin (600 mg daily for 21 days) reduced steady-state osimertinib exposure (AUC) by 78% in a clinical pharmacokinetic study; concomitant use with Tagrisso (osimertinib mesylate) should be avoided.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 32Document updated
Sources checked